Kymera Therapeutics, Inc.
KYMR
$24.12
$1.727.68%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 97.65% | -85.42% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 97.65% | -85.42% | |||
| Cost of Revenue | 18.88% | 2.04% | |||
| Gross Profit | -13.68% | -68.90% | |||
| SG&A Expenses | 5.67% | -11.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.19% | -0.93% | |||
| Operating Income | -11.97% | -41.63% | |||
| Income Before Tax | -13.23% | -48.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.23% | -48.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.23% | -48.56% | |||
| EBIT | -11.97% | -41.63% | |||
| EBITDA | -14.30% | -43.17% | |||
| EPS Basic | -7.76% | -42.57% | |||
| Normalized Basic EPS | -7.76% | -42.58% | |||
| EPS Diluted | -7.76% | -42.57% | |||
| Normalized Diluted EPS | -7.76% | -42.58% | |||
| Average Basic Shares Outstanding | 5.07% | 4.20% | |||
| Average Diluted Shares Outstanding | 5.07% | 4.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
